Loading organizations...
§ Private Profile · Basel, Switzerland
Clinical-stage immunology company developing therapeutic antibodies for inflammation, autoimmunity, and fibrosis.
Granite Bio is a clinical-stage immunology company developing first-in-class therapeutic antibodies that target fundamental drivers of inflammation, autoimmunity, and fibrosis, based in Basel, Switzerland. The company emerged from stealth in April 2025 with $100 million in total funding, comprising a $30 million Series A and a $70 million Series B round. Its pipeline includes GRT-001, an antibody addressing allergy and itchiness, and GRT-002, which is currently preclinical and anticipated to enter clinical trials by 2026. These therapies, developed using Versant’s Ridgeline Discovery Engine, selectively deplete pathogenic cells. Key investors include Versant Ventures, Novartis Venture Fund, Forbion, and Sanofi Ventures, with Patrick Loustau serving as President and CEO. Granite Bio was founded in 2021 by Versant Ventures and Novartis Venture Fund.
Granite Bio has raised $70.0M across 1 funding round.
Granite Bio has raised $70.0M in total across 1 funding round.
Granite Bio has raised $70.0M in total across 1 funding round.
Granite Bio's investors include Forbion, Versant Ventures, Novartis Venture Fund.
Granite Bio has raised $70.0M across 1 funding round. Most recently, it raised $70.0M Series B in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $70M Series B | Forbion, Versant Ventures | Novartis Venture Fund | Announced |
Granite Bio is a Basel-based, clinical-stage biotechnology company developing first-in-class antibody therapies that target fundamental drivers of inflammation, autoimmunity, and fibrosis.[1][2][3] Its lead product, GRT-001, depletes pro-inflammatory monocytes to address autoimmune diseases like inflammatory bowel disease (IBD), currently in Phase 1a trials with healthy volunteers and advancing to Phase 1b in IBD patients later in 2025; the second candidate, GRT-002, inhibits interleukin-3 (IL-3) for autoimmune and type II inflammation (e.g., itch and allergies), slated for clinical trials in 2026.[2][3][4] Granite Bio serves patients with unmet needs in inflammatory disorders where existing therapies often fail to provide lasting control, solving root-cause issues rather than symptoms to potentially "reset" immune systems and improve outcomes.[1][4][6] Emerging from stealth in May 2025 with $100 million in funding ($30M Series A led by Versant Ventures and Novartis Venture Fund; $70M Series B led by Forbion and Sanofi Ventures), the company shows strong early momentum backed by top-tier investors and preclinical success in non-human primates.[1][3][5]
Granite Bio was founded by Versant Ventures and Novartis Venture Fund, emerging from stealth on May 13, 2025, with its lead molecules originating from the labs of Professor Matthias Mack, scientific co-founder at the University of Regensburg.[1][3][5] The antibodies were developed in collaboration with Versant’s Ridgeline Discovery Engine in Basel, Switzerland, leveraging this platform to pioneer therapies targeting core disease pathways in immunology.[1][3][6] Key leadership includes Patrick Loustau as President and CEO, who emphasizes addressing urgent unmet needs in inflammation and autoimmunity.[1][6][7] Early traction came from robust preclinical data, including dose-dependent monocyte depletion in non-human primates for GRT-001, which was well-tolerated and spared essential tissue macrophages, setting the stage for rapid clinical entry.[3][4][5]
Granite Bio rides the surging wave of immunology innovation, where venture capital targets next-generation therapies amid limitations of current drugs like B-cell depleters, which often lead to relapse in autoimmune diseases.[3][4] Timing is ideal post-2025 funding boom in biotech, fueled by advances in antibody discovery engines like Ridgeline and growing markets for IBD (e.g., ulcerative colitis) and type II inflammation (allergies, itch), projected as multi-billion opportunities.[1][4][5] Market forces favoring Granite include rising demand for disease-modifying agents that target innate immunity's "cellular source," potentially expanding beyond IBD to fibrosis and broader autoimmunity, influencing the ecosystem by validating monocyte/IL-3 approaches and accelerating Versant-style platform spinouts.[3][4][6]
Granite Bio is poised for milestone-driven growth, with GRT-001 Phase 1b data in IBD expected late 2025 and GRT-002 trials in 2026, potentially unlocking partnerships or further funding amid hot immunology M&A.[2][4] Trends like AI-enhanced discovery (via Ridgeline) and precision immune modulation will shape its path, amplifying influence as a leader in root-cause therapies if clinical results confirm preclinical promise.[1][3] As a Versant creation with blue-chip backers, Granite could redefine autoimmune treatment standards, transforming patient lives where others fall short and solidifying Basel's biotech hub status—watch for proof-of-concept readouts to catalyze its next leap.[4][6][7]